Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy
11:35am, Wednesday, 18'th Aug 2021
Basel, 18 August 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company's commitment to perso
Roche says arthritis drug authorized to treat hospitalized COVID-19 patients is in short supply
03:01pm, Tuesday, 17'th Aug 2021
Roche Holding AG ROG, +0.45% said Monday that Actemra, its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short sup
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
07:47am, Tuesday, 17'th Aug 2021
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after showing it cut the risk of death. Less tha
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
04:06pm, Monday, 09'th Aug 2021
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its prima
Valuations Matter: 5 Bargains In A Sea Of Overvalued Monsters
07:13am, Monday, 09'th Aug 2021
Valuations Matter: 5 Bargains In A Sea Of Overvalued Monsters
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the pivotal Phase III POLARIX trial investigating Polivy® (pola
Here Are the Winners of Cowen's Big Pharma R&D Showdown
10:02am, Saturday, 07'th Aug 2021
The Wall Street firm put big drugmakers' R&D programs through five different tests.
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
09:39am, Wednesday, 04'th Aug 2021
An effective oral antiviral therapy for the coronavirus may be around the corner.
SoftBank Said to Build $5 Billion Stake in Roche
09:06pm, Tuesday, 03'rd Aug 2021
Aug.03 -- Bloomberg has learned that SoftBank Group Corp. has built a $5 billion stake in Roche Holding AG, placing a big bet on the pharma giant's strategy of using data to develop drugs. We've also
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
06:32am, Tuesday, 03'rd Aug 2021
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for certain patients with early non-small cell lung c
US FDA grants Priority Review to Roche's Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
01:00am, Tuesday, 03'rd Aug 2021
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) an
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
06:03am, Monday, 02'nd Aug 2021
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody cocktail. REGEN-COV (casirivi
Roche's Faricimab US Application For Ocular Diseases Under Priority Review
08:03am, Thursday, 29'th Jul 2021
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular degeneration (nAMD) and diabetic macular
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA), under Priority
Basel, 29 July 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine (NEJM) has published data from FIREFISH Part 2, a pivotal global study evaluating th
